Karyopharm Therapeutics (KPTI) Competitors $4.23 -0.16 (-3.64%) Closing price 04:00 PM EasternExtended Trading$4.40 +0.17 (+4.02%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KPTI vs. BIOA, IKT, BDTX, ALEC, TIL, GALT, LXEO, KYTX, RAPT, and LYELShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include BioAge Labs (BIOA), Inhibikase Therapeutics (IKT), Black Diamond Therapeutics (BDTX), Alector (ALEC), Instil Bio (TIL), Galectin Therapeutics (GALT), Lexeo Therapeutics (LXEO), Kyverna Therapeutics (KYTX), Rapt Therapeutics (RAPT), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Its Competitors BioAge Labs Inhibikase Therapeutics Black Diamond Therapeutics Alector Instil Bio Galectin Therapeutics Lexeo Therapeutics Kyverna Therapeutics Rapt Therapeutics Lyell Immunopharma Karyopharm Therapeutics (NASDAQ:KPTI) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability. Which has higher valuation & earnings, KPTI or BIOA? BioAge Labs has lower revenue, but higher earnings than Karyopharm Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$145.24M0.25-$76.42M-$13.26-0.32BioAge LabsN/AN/A-$71.11MN/AN/A Do analysts prefer KPTI or BIOA? Karyopharm Therapeutics presently has a consensus target price of $43.20, suggesting a potential upside of 921.28%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than BioAge Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00BioAge Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in KPTI or BIOA? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 2.8% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 20.8% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to KPTI or BIOA? In the previous week, Karyopharm Therapeutics had 1 more articles in the media than BioAge Labs. MarketBeat recorded 3 mentions for Karyopharm Therapeutics and 2 mentions for BioAge Labs. Karyopharm Therapeutics' average media sentiment score of 0.00 beat BioAge Labs' score of -0.17 indicating that Karyopharm Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is KPTI or BIOA more profitable? BioAge Labs has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -43.99%. Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-43.99% N/A -35.95% BioAge Labs N/A N/A N/A SummaryKaryopharm Therapeutics beats BioAge Labs on 7 of the 11 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.55M$2.37B$5.45B$8.93BDividend YieldN/A1.78%5.22%4.01%P/E Ratio-0.328.8727.2420.06Price / Sales0.25660.97426.37117.54Price / CashN/A21.7726.2128.59Price / Book-0.194.497.925.56Net Income-$76.42M$31.26M$3.17B$248.56M7 Day Performance-1.86%5.49%4.40%7.56%1 Month Performance-5.79%5.83%2.64%8.54%1 Year Performance-65.56%9.11%35.04%21.81% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics3.804 of 5 stars$4.23-3.6%$43.20+921.3%-62.4%$36.55M$145.24M-0.32380BIOABioAge LabsN/A$4.13-1.7%N/AN/A$148.06MN/A0.00N/AIKTInhibikase Therapeutics1.3436 of 5 stars$1.95+20.4%$6.50+233.3%+62.9%$144.97M$260K-0.736BDTXBlack Diamond Therapeutics3.1073 of 5 stars$2.48+5.5%$14.60+488.7%-42.3%$141.01MN/A41.3390Positive NewsGap DownALECAlector3.7977 of 5 stars$1.40-5.4%$4.00+185.7%-66.4%$139.99M$100.56M-1.11270TILInstil Bio2.9568 of 5 stars$20.83-9.3%$119.00+471.3%+185.4%$136.62MN/A-1.74410GALTGalectin Therapeutics1.6317 of 5 stars$2.11-9.4%$6.00+184.4%+4.6%$133.54MN/A-2.939LXEOLexeo Therapeutics1.8733 of 5 stars$4.02-2.4%$16.60+312.9%-71.4%$133.46M$650K-1.2258News CoverageKYTXKyverna Therapeutics1.2757 of 5 stars$3.07-6.4%$18.50+502.6%-58.7%$132.69M$7.03M-0.9196RAPTRapt Therapeutics4.1986 of 5 stars$8.00-5.1%$24.00+200.0%-63.7%$132.32M$1.53M-0.4280LYELLyell Immunopharma2.5841 of 5 stars$8.84-1.1%$15.00+69.7%-67.5%$130.92M$60K-0.35270 Related Companies and Tools Related Companies BioAge Labs Competitors Inhibikase Therapeutics Competitors Black Diamond Therapeutics Competitors Alector Competitors Instil Bio Competitors Galectin Therapeutics Competitors Lexeo Therapeutics Competitors Kyverna Therapeutics Competitors Rapt Therapeutics Competitors Lyell Immunopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KPTI Stock Alerts